PMID- 19922106
OWN - NLM
STAT- MEDLINE
DCOM- 20100222
LR  - 20181201
IS  - 1651-2251 (Electronic)
IS  - 0001-6489 (Linking)
VI  - 129
IP  - 12
DP  - 2009 Dec
TI  - In situ tissue engineering of canine skull with guided bone regeneration.
PG  - 1509-18
LID - 10.3109/00016480902801212 [doi]
AB  - CONCLUSION: Calcium alginate (CA) membrane prevents excessive fibrous tissue 
      intrusion and/or dislocation of a bone scaffold. However, CA membrane did not 
      always accelerate cranial bone regeneration. OBJECTIVE: We previously reported 
      skull regeneration using a bone substitute material (BSM), which consisted of 
      collagen-coated beta-tricalcium phosphate and autologous bone fragments, and bone 
      marrow-derived stromal cells (BSCs). However, excessive fibrous tissue intrusion 
      or dislocation of the BSM occasionally interrupted bone regeneration. To avoid 
      such problems, we examined CA membrane, which is useful for guided bone 
      regeneration (GBR), to investigate whether this material maintains the bone 
      regenerative space. MATERIALS AND METHODS: Bone defects (2x2 cm) were created in 
      the skulls of 12 adult beagle dogs using the same clinical procedure. Four 
      experimental models were tested with or without BSM plus BSCs or CA membrane. In 
      group I, the original free bone flap was replaced at the defect. In group II, 
      after replacing the bone flap, the defect was covered with CA membrane. In group 
      III, BSM plus BSCs were used as a gap filler. In group IV, BSM plus BSCs and CA 
      membrane were applied. Histological examinations were performed 3 and 6 months 
      after the operation. RESULTS: In groups I and II, bone regeneration was not 
      observed but fibrous tissue intrusion was prevented in group II. Bone neogenesis 
      was more observed in group III than in group IV at 3 months (p<0.05). At 6 
      months, the regenerated areas were larger than those observed at 3 months, but 
      the differences between groups III and IV were not statistically significant.
FAU - Umeda, Hiroo
AU  - Umeda H
AD  - Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, 
      Fukushima Medical University, School of Medicine, Fukushima, Japan.
FAU - Kanemaru, Shin-Ichi
AU  - Kanemaru S
FAU - Yamashita, Masaru
AU  - Yamashita M
FAU - Ohno, Tsunehisa
AU  - Ohno T
FAU - Suehiro, Atsushi
AU  - Suehiro A
FAU - Tamura, Yoshihiro
AU  - Tamura Y
FAU - Hirano, Shigeru
AU  - Hirano S
FAU - Nakamura, Tatsuo
AU  - Nakamura T
FAU - Omori, Koichi
AU  - Omori K
FAU - Ito, Juichi
AU  - Ito J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Acta Otolaryngol
JT  - Acta oto-laryngologica
JID - 0370354
RN  - 0 (Alginates)
RN  - 0 (Biocompatible Materials)
RN  - 0 (Hexuronic Acids)
RN  - 8A5D83Q4RW (Glucuronic Acid)
SB  - IM
MH  - Alginates/*therapeutic use
MH  - Animals
MH  - Biocompatible Materials/*therapeutic use
MH  - *Bone Regeneration
MH  - Dogs
MH  - Glucuronic Acid/therapeutic use
MH  - Hexuronic Acids/therapeutic use
MH  - Skull Fractures/*therapy
MH  - *Tissue Engineering
EDAT- 2009/11/20 06:00
MHDA- 2010/02/23 06:00
CRDT- 2009/11/20 06:00
PHST- 2009/11/20 06:00 [entrez]
PHST- 2009/11/20 06:00 [pubmed]
PHST- 2010/02/23 06:00 [medline]
AID - 10.3109/00016480902801212 [pii]
AID - 10.3109/00016480902801212 [doi]
PST - ppublish
SO  - Acta Otolaryngol. 2009 Dec;129(12):1509-18. doi: 10.3109/00016480902801212.